{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:18:00Z","timestamp":1783448280994,"version":"3.55.0"},"reference-count":29,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":106,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>In the SELECT cardiovascular (CV) outcomes trial, semaglutide 2.4 mg significantly reduced all-cause mortality or non-fatal CV events versus placebo in patients with CV disease (CVD) and overweight\/obesity, but without type 2 diabetes (T2D). By applying results from SELECT to a UK real-world population, this present cohort study evaluated the impact of semaglutide on life expectancy and CV event-free life-years. Included were individuals from the Discover electronic health record database who met SELECT eligibility criteria (\u226545 years old; body mass index: \u226527 kg\/m2; established CVD; no T2D). The Discover database comprises linked primary and secondary care data covering people residing in North West London, UK. Cohort entry was the first date between 2004 and 2019 when all inclusion criteria were met. Effect estimates from SELECT were applied using actuarial life tables, estimating the effect of semaglutide on life expectancy overall and by age group. Life expectancy gains and CV event-free life expectancy were estimated using the Arriaga and Sullivan methods, respectively. In total, 19,117 individuals aged \u226545 years were included in the main analysis (63% men; mean age: 65.4 years). The estimated gain in life expectancy with semaglutide treatment was 1.9 years. A CV event-free life-year gain of 2.0 years was predicted with semaglutide. Life-year gains were observed across all age groups but were higher for younger age groups. Based on SELECT data, semaglutide is predicted to increase life expectancy and CV event-free life-years in a real-world population with overweight\/obesity and CVD, particularly in younger people.<\/jats:p>","DOI":"10.1530\/ec-25-0903","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:09:29Z","timestamp":1773058169000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":0,"title":["Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK"],"prefix":"10.1530","volume":"15","author":[{"given":"Thomas","family":"Van Sloten","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H J","family":"Hageman","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Westerink","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Capucci","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Diogo da Rocha Fernandes","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Holloway","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pijper","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Tikhonovsky","sequence":"additional","affiliation":[{"name":"4"},{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Emerson","sequence":"additional","affiliation":[{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Michael","family":"Lincoff","sequence":"additional","affiliation":[{"name":"7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Plutzky","sequence":"additional","affiliation":[{"name":"8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7006-7401","authenticated-orcid":true,"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[{"name":"9"},{"name":"10"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2026070713505874300_bib1","article-title":"Global health estimates: life expectancy and healthy life expectancy","author":"World Health Organization (WHO)","year":"2024"},{"key":"2026070713505874300_bib2","article-title":"National life tables \u2013 life expectancy in the UK: 2021 to 2023","author":"Office for National Statistics (ONS)","year":"2025"},{"key":"2026070713505874300_bib3","first-page":"321","article-title":"Reversing the decreasing life expectancy: a national health priority","volume":"119","author":"Lichtenberg","year":"2022","journal-title":"Mo Med"},{"key":"2026070713505874300_bib4","first-page":"2165","article-title":"The main causes of death in patients with COVID-19","volume":"27","author":"Oboza","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026070713505874300_bib5","article-title":"Global health estimates: life expectancy and leading causes of death and disability","author":"World Health Organization (WHO)","year":"2024"},{"key":"2026070713505874300_bib6","article-title":"Understanding the drivers of healthy life expectancy: report","author":"Office for Health Improvement & Disparities (OHID)","year":"2023"},{"key":"2026070713505874300_bib7","article-title":"BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants","volume":"353","author":"Aune","year":"2016","journal-title":"BMJ"},{"key":"2026070713505874300_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2012.113905","article-title":"Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis","volume":"309","author":"Flegal","year":"2013","journal-title":"JAMA"},{"key":"2026070713505874300_bib9","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0140-6736(14)60460-8","article-title":"Global, regional, and national prevalence of overweight and obesity in children and adults during 1980\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"384","author":"Ng","year":"2014","journal-title":"Lancet"},{"key":"2026070713505874300_bib10","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/eurjpc\/zwac187","article-title":"Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation","volume":"29","author":"Lopez-Jimenez","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026070713505874300_bib11","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1001\/archinte.167.16.1720","article-title":"Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons","volume":"167","author":"Bogers","year":"2007","journal-title":"Arch Intern Med"},{"key":"2026070713505874300_bib12","article-title":"Obesity and overweight","author":"World Health Organization (WHO)","year":"2024"},{"key":"2026070713505874300_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287218","article-title":"Body mass index and all-cause mortality in a 21st century U.S. population: A National Health Interview Survey Analysis","volume":"18","author":"Visaria","year":"2023","journal-title":"PLoS One"},{"key":"2026070713505874300_bib14","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070713505874300_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12911-020-1082-7","article-title":"How an electronic health record became a real-world research resource: comparison between London\u2019s Whole Systems Integrated Care database and the Clinical Practice Research Datalink","volume":"20","author":"Bottle","year":"2020","journal-title":"BMC Med Inform Decis Mak"},{"key":"2026070713505874300_bib16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S2213-8587(22)00033-X","article-title":"Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study","volume":"10","author":"Kivimaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070713505874300_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2307\/4594169","article-title":"A single index of mortality and morbidity","volume":"86","author":"Sullivan","year":"1971","journal-title":"HSMHA Health Rep"},{"key":"2026070713505874300_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2307\/2061029","article-title":"Measuring and explaining the change in life expectancies","volume":"21","author":"Arriaga","year":"1984","journal-title":"Demography"},{"key":"2026070713505874300_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/heartjnl-2015-307668","article-title":"Estimated 10-year cardiovascular mortality seriously underestimates overall cardiovascular risk","volume":"102","author":"Jorstad","year":"2016","journal-title":"Heart"},{"key":"2026070713505874300_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038761","article-title":"Comparison of cardiovascular disease risk factors, assessment and management in men and women, including consideration of absolute risk: a nationally representative cross-sectional study","volume":"10","author":"Banks","year":"2020","journal-title":"BMJ Open"},{"key":"2026070713505874300_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.100950","article-title":"Prevalence and clinical characteristics of patients with hsCRP testing and test-confirmed systemic inflammation among individuals with atherosclerotic cardiovascular disease with or without chronic kidney disease in the United States (PLUTUS)","volume":"21","author":"Lv","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"2026070713505874300_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5992","article-title":"Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study","volume":"349","author":"Leening","year":"2014","journal-title":"BMJ"},{"key":"2026070713505874300_bib23","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.hjc.2020.09.015","article-title":"Cardiovascular disease in women: executive summary of the expert panel statement of women in cardiology of the hellenic cardiological society","volume":"61","author":"Chrysohoou","year":"2020","journal-title":"Hellenic J Cardiol"},{"key":"2026070713505874300_bib24","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s12471-010-0841-y","article-title":"Gender differences in coronary heart disease","volume":"18","author":"Maas","year":"2010","journal-title":"Neth Heart J"},{"key":"2026070713505874300_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001361","article-title":"Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study","volume":"9","author":"Ferket","year":"2012","journal-title":"PLoS Med"},{"key":"2026070713505874300_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0735-1097(02)01914-9","article-title":"Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels","volume":"40","author":"Blake","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026070713505874300_bib27","article-title":"Cardiovascular disease: risk assessment and reduction, including lipid modification","author":"National Institute for Health and Care Excellence (NICE)","year":"2023"},{"key":"2026070713505874300_bib28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2022.12138","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"328","author":"Chou","year":"2022","journal-title":"JAMA"},{"key":"2026070713505874300_bib29","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod","year":"2023","journal-title":"Diabetes Obes Metab"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/15\/3\/EC-25-0903.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/15\/3\/EC-25-0903.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0903\/504517\/ec-25-0903.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0903\/504517\/ec-25-0903.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:53:19Z","timestamp":1783446799000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/15\/3\/e250903\/75332\/Projected-life-year-gains-with-semaglutide-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-25-0903","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"article-number":"e250903"}}